NCT06156267View on ClinicalTrials.gov

Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

March 31, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Adebrelimab

Adebrelimab is a programmed death-ligand 1 antibody.

DRUG

mRNA tumor vaccines

neoantigen personalized mRNA vaccines

Trial Locations (1)

200032

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai

All Listed Sponsors
collaborator

Shanghai Regenelead Therapies Co., Ltd.

INDUSTRY

lead

Fudan University

OTHER

NCT06156267 - Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | Biotech Hunter | Biotech Hunter